AbbVie (ABBV) exec. says they anticipate aesthetics growth will remain challenged in 2026 and are focused on investing to stimulate the market

AbbVie anticipates challenges in its aesthetics growth through 2026, which could weigh on investor sentiment, especially as they plan to invest in stimulating the market.

Newsquawk StaffPublished On the live feed at 6 more headlines followed before this page went public
Newsquawk headlinesUTC

Canadian S&P Global Services PMI (Jan) 45.8 (Prev. 46.5)

EU diplomats say EU ambassadors agreed on a EUR 90bln loan for Ukraine

AbbVie (ABBV) exec. says they anticipate aesthetics growth will remain challenged in 2026 and are focused on investing to stimulate the market

US VP Vance proposes a trading bloc for critical minerals, adds the US will establish a system for creating price floors for critical minerals

Ford (F) reports January US sales -5.3% Y/Y, US EV sales -25% Y/Y, US F-Series Pickup Truck sales -18% Y/Y

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • Expects 2026 Skyrizi revenue of USD 21.5bln and Rinvoq revenue of USD 10bln.
  • Expects 2026 revenue of aesthetic sales to reach USD 5bln including Botox cosmetic revenue of USD 2.7bln.
  • Expects Q1 adj. EPS between 2.97-3.01 (exp. 3.07); Net revenue approx. 14.7bln (exp. 14.85bln).
Context

The expected revenue figures, particularly for Skyrizi and Rinvoq, imply a continued focus on their core therapeutic markets, but the slight miss on Q1 EPS and net revenue relative to expectations may raise some eyebrows about their overall outlook. Traders should watch how these developments influence market perception and stock performance, particularly in relation to competitors in the biotech space.

Related headlines

The whole workspace, free to try.

Try it free